Daiichi Closing Indian Site As Global Restructuring Continues
Executive Summary
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
You may also be interested in...
More US Positions Go As Daiichi Sankyo Refocuses
Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.
Daiichi Seeks To Stall Singh Asset Sales In Ranbaxy Compensation Battle
Daiichi Sankyo has chalked up a procedural win in its ongoing court battle for compensation from Indian tycoons Malvinder and Shivinder Singh over the Japanese company’s ill-fated acquisition of Indian generic giant Ranbaxy.
Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals
Now that Kite Pharma Inc.’s first chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (KTE-C19) is being submitted for US FDA approval, Chairman, President and CEO Arie Belldegrun said it is the right time to think about ways to make the company’s technology available in additional markets, like Japan and China where Kite entered into partnership agreements with Daiichi Sankyo Co. Ltd. and Shanghai Fosun Pharmaceutical Group Co. Ltd., respectively.